 SOUTH PLAINFIELD, N.J., March 15, 2021 PRNewswire -- PTC Therapeutics, Inc. NASDAQ: PTCT today announced results from a real-world study of patients with Duchenne muscular dystrophy DMD and Becker muscular dystrophy BMD who switched from prednisone to EMFLAZA deflazacort following the FDA approval. 